Citius Pharmaceuticals (NASDAQ: ALDX) and Aldeyra Therapeutics (NASDAQ:ALDX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, valuation, dividends, institutional ownership, profitability and risk.
This table compares Citius Pharmaceuticals and Aldeyra Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a summary of recent ratings and price targets for Citius Pharmaceuticals and Aldeyra Therapeutics, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Citius Pharmaceuticals presently has a consensus price target of $11.00, suggesting a potential upside of 685.71%. Aldeyra Therapeutics has a consensus price target of $21.00, suggesting a potential upside of 167.52%. Given Citius Pharmaceuticals’ stronger consensus rating and higher possible upside, equities research analysts clearly believe Citius Pharmaceuticals is more favorable than Aldeyra Therapeutics.
Volatility and Risk
Citius Pharmaceuticals has a beta of 3.78, indicating that its share price is 278% more volatile than the S&P 500. Comparatively, Aldeyra Therapeutics has a beta of 0.55, indicating that its share price is 45% less volatile than the S&P 500.
Institutional and Insider Ownership
3.2% of Citius Pharmaceuticals shares are held by institutional investors. Comparatively, 57.8% of Aldeyra Therapeutics shares are held by institutional investors. 52.1% of Citius Pharmaceuticals shares are held by insiders. Comparatively, 17.0% of Aldeyra Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Earnings & Valuation
This table compares Citius Pharmaceuticals and Aldeyra Therapeutics’ gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Citius Pharmaceuticals||N/A||N/A||-$10.38 million||N/A||N/A|
|Aldeyra Therapeutics||N/A||N/A||-$22.34 million||($1.40)||-5.61|
Citius Pharmaceuticals beats Aldeyra Therapeutics on 7 of the 9 factors compared between the two stocks.
About Citius Pharmaceuticals
Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes critical care products. It primarily focuses on developing anti-infective, cancer care, and prescription products. The company develops Mino-Lok product, which has completed Phase IIb clinical trials for the treatment and salvage of infected central venous catheters in patients with catheter related bloodstream infections; and Hydro-Lido product, a topical formulation of hydrocortisone and lidocaine that is intended for the treatment of hemorrhoids. It has a collaboration and license agreement with Alpex Pharma S.A. to develop and commercialize orally disintegrating tablet formulations of pharmaceutical products in United States, Canada, and Mexico. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.
About Aldeyra Therapeutics
Aldeyra Therapeutics, Inc., a biotechnology company, focuses on the development of products for inflammation, inborn errors of metabolism, and other diseases in the United States and internationally. It is developing ADX-102, a small molecule designed to trap and allow for the degradation of aldehydes, as well as ADX-103 and ADX-104 novel candidates for the treatment of noninfectious anterior uveitis, allergic conjunctivitis, dry eye syndrome, sjögren-larsson syndrome, and succinic semi-aldehyde dehydrogenase deficiency. Aldeyra Therapeutics, Inc. has a collaborative research agreement with Janssen Research & Development, LLC for the development of novel immune-modulating drugs for systemic inflammatory diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was founded in 2004 and is headquartered in Lexington, Massachusetts.
Receive News & Ratings for Citius Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Citius Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.